India Daybook: April 28, 2026

The Indian stock market remains in high gear as the Q4 earnings season intensifies with heavyweights like Maruti Suzuki and Bandhan Bank set to report today. Investor sentiment is further bolstered by Sun Pharma's landmark $12 billion acquisition of Organon and significant progress in the NSE IPO process.

🇮🇳 India Daybook: Sun Pharma's Mega $12B Acquisition, Maruti & Bandhan Bank Q4 Results in Focus

Indian markets are bracing for a high-impact Tuesday as the monthly F&O expiry coincides with critical earnings from the auto and banking sectors. Corporate India is making global waves with Sun Pharma announcing its largest-ever overseas acquisition, while the pharmaceutical sector continues to see a string of USFDA approvals and product launches.

📍 EARNINGS

• Maruti Suzuki: The auto major is scheduled to report its Q4 and full-year FY26 results today. Markets will closely monitor volume growth in the PV segment and dividend announcements.
• Bandhan Bank: To report Q4 results today; focus will be on asset quality and loan book growth.
• Hindustan Zinc: Reported a 68% YoY jump in Q4 net profit to ₹5,033 crore, driven by higher production and silver prices; announced an interim dividend of ₹11 per share.
• M&M Financial Services: Q4 net profit surged 106% YoY to ₹940 crore; the board recommended a dividend of ₹7.5 per share.
• Shriram Finance: Reported a robust 41% YoY increase in Q4 net profit to ₹3,014 crore.
• Ceat & Eternal: Both companies are slated to release their quarterly earnings during the day.

📍 ACQUISITION

• Sun Pharma: Announced a definitive agreement to acquire US-based Organon & Co. for $12 billion, marking the largest-ever overseas acquisition by an Indian pharmaceutical company.
• Gujarat Themis Biosyn: Recently completed the acquisition of Sanofi’s tuberculosis drug portfolio to expand its domestic presence.

📍 PHARMA & USFDA

• Alembic Pharmaceuticals: Received final USFDA approval for Fingolimod Capsules (0.5 mg), a generic equivalent to Novartis’ Gilenya used for treating multiple sclerosis.
• Lupin: Launched generic Dapagliflozin and Metformin Hydrochloride extended-release tablets in the US market following USFDA approval.
• Cipla: Secured USFDA approval for the first AB-rated generic version of Ventolin HFA (Albuterol Sulfate Inhalation Aerosol).

📍 ORDER WIN

• Coforge: Bagged a significant five-year contract worth $158 million (approx. ₹1,234 crore) from a UK-based client, with revenue recognition starting in April 2026.
• Adani Power: Its subsidiary, Moxie Power Generation, secured a 558 MW electricity supply pact from Tamil Nadu Power Distribution Corporation for five years.
• KEC International: Secured new orders worth ₹1,002 crore across its transmission, distribution, and global tower supply segments.

📍 CORPORATE ACTIONS

• National Stock Exchange (NSE): The proposed IPO received a boost as shareholders agreed to divest over 4% of the bourse's total equity capital through an Offer for Sale (OFS).
• Vedanta: Trading in focus ahead of its demerger record date; the company plans to list four new businesses (Aluminium, Power, Oil & Gas, and Iron & Steel) separately.
• LANXESS: Inaugurated a new ₹150 crore lubricant additives plant in Gujarat and signed an MoU with Indian Oil Corporation (IOCL).

📍 MACRO & POLICY

• RBI Auction: The Reserve Bank of India is conducting an auction of ₹14,500 crore in State Government Securities (SGS) today for various states including UP, Bihar, and Kerala.
• India-New Zealand FTA: Prime Minister Modi hailed the newly signed Free Trade Agreement as a "historic milestone" that grants duty-free access to 100% of Indian exports.

TAGS: India Daybook, Stocks in News, Corporate News, Stock Market, Company News

Tags: India Daybook Stocks in News Corporate News Stock Market Company News